Core Viewpoint - The company is set to acquire a 49% stake in Optimed Holding GmbH for approximately €18.375 million, marking a significant step in its global expansion strategy and enhancing its competitive position in the medical technology sector [1][2]. Group 1 - The acquisition represents a key milestone in the company's long-term commitment to global expansion, facilitating entry into European and global markets [2]. - The integration of assets is expected to accelerate the company's international strategy, diversify its product portfolio, and expand its global distribution network [2]. - The transaction aims to create significant manufacturing and operational synergies between Germany and China, enhancing product quality and operational efficiency [2]. Group 2 - The acquisition will enable the company to fully leverage its efficient R&D capabilities, expanding its innovative solutions to global markets [3]. - Post-acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, to enhance international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside of mainland China, significantly boosting the company's international sales efforts [3].
归创通桥(02190)拟1837.5万欧元收购Optimed Holding 49%股权 为进军欧洲及全球市场的关键里程碑